Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2012, Article ID 785946, 9 pages
http://dx.doi.org/10.1155/2012/785946
Review Article

Atherogenic Index and High-Density Lipoprotein Cholesterol as Cardiovascular Risk Determinants in Rheumatoid Arthritis: The Impact of Therapy with Biologicals

Department of Rheumatology, Radboud University Nijmegen Medical Centre, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands

Received 22 July 2012; Accepted 1 August 2012

Academic Editor: Miguel A. González-Gay

Copyright © 2012 Calin D. Popa et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. E. Gabriel, C. S. Crowson, H. M. Kremers et al., “Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years,” Arthritis & Rheumatism, vol. 48, no. 1, pp. 54–58, 2003. View at Publisher · View at Google Scholar · View at Scopus
  2. T. Pincus, T. Sokka, and F. Wolfe, “Premature mortality in patients with rheumatoid arthritis: evolving concepts,” Arthritis & Rheumatism, vol. 44, no. 6, pp. 1234–1236, 2001. View at Google Scholar
  3. I. del Rincón, K. Williams, M. P. Stern, G. L. Freeman, and A. Escalante, “High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors,” Arthritis & Rheumatism, vol. 44, no. 12, pp. 2737–2745, 2001. View at Google Scholar
  4. R. Ross, “Atherosclerosis—an inflammatory disease,” The New England Journal of Medicine, vol. 340, no. 2, pp. 115–126, 1999. View at Publisher · View at Google Scholar · View at Scopus
  5. N. Sattar, D. W. McCarey, H. Capell, and I. B. McInnes, “Explaining how “high-grade” systemic inflammation accelerates vascular risk in rheumatoid arthritis,” Circulation, vol. 108, no. 24, pp. 2957–2963, 2003. View at Publisher · View at Google Scholar · View at Scopus
  6. S. Van Doornum, G. McColl, and I. P. Wicks, “Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis?” Arthritis & Rheumatism, vol. 46, no. 4, pp. 862–873, 2002. View at Publisher · View at Google Scholar · View at Scopus
  7. J. S. Smolen, R. Landewé, F. C. Breedveld et al., “EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs,” Annals of the Rheumatic Diseases, vol. 69, no. 6, pp. 964–975, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. T. E. Toms, V. F. Panoulas, K. M. J. Douglas et al., “Statin use in rheumatoid arthritis in relation to actual cardiovascular risk: evidence for substantial undertreatment of lipid-associated cardiovascular risk?” Annals of the Rheumatic Diseases, vol. 69, no. 4, pp. 683–688, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. M. J. L. Peters, D. P. M. Symmons, D. McCarey et al., “EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis,” Annals of the Rheumatic Diseases, vol. 69, no. 2, pp. 325–331, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. M. McMahon, J. Grossman, J. FitzGerald et al., “Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis,” Arthritis & Rheumatism, vol. 54, no. 8, pp. 2541–2549, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. C. Popa, L. J. H. van Tits, P. Barrera et al., “Anti-inflammatory therapy with tumour necrosis factor alpha inhibitors improves high-density lipoprotein cholesterol antioxidative capacity in rheumatoid arthritis patients,” Annals of the Rheumatic Diseases, vol. 68, no. 6, pp. 868–872, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. Y. B. Park, S. K. Lee, W. K. Lee et al., “Lipid profiles in untreated patients with rheumatoid arthritis,” Journal of Rheumatology, vol. 26, no. 8, pp. 1701–1704, 1999. View at Google Scholar · View at Scopus
  13. V. P. van Halm, M. M. J. Nielen, M. T. Nurmohamed et al., “Lipids and inflammation: serial measurements of the lipid profile of blood donors who later developed rheumatoid arthritis,” Annals of the Rheumatic Diseases, vol. 66, no. 2, pp. 184–188, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. S. Ajeganova, R. Fiskesund, U. de Faire, I. Hafstrom, and J. Frostegard, “Effect of biological therapy on levels of atheroprotective antibodies against phosphorylcholine and apolipoproteins in rheumatoid arthritis—a one year study,” Clinical and Experimental Rheumatology, vol. 29, no. 6, pp. 942–950, 2011. View at Google Scholar
  15. Y. Allanore, A. Kahan, J. Sellam, O. G. Ekindjian, and D. Borderie, “Effects of repeated infliximab therapy on serum lipid profile in patients with refractory rheumatoid arthritis,” Clinica Chimica Acta, vol. 365, no. 1-2, pp. 143–148, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. J. R. Curtis, A. John, and O. Baser, “Dyslipidemia and changes in lipid profiles associated with rheumatoid arthritis and initiation of anti-TNF therapy,” Arthritis Care and Research, vol. 64, no. 9, pp. 1251–1282, 2012. View at Google Scholar
  17. S. R. Dahlqvist, S. Engstrand, E. Berglin, and O. Johnson, “Conversion towards an atherogenic lipid profile in rheumatoid arthritis patients during long-term infliximab therapy,” Scandinavian Journal of Rheumatology, vol. 35, no. 2, pp. 107–111, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. I. L. Engvall, B. Tengstrand, K. Brismar, and I. Hafström, “Infliximab therapy increases body fat mass in early rheumatoid arthritis independently of changes in disease activity and levels of leptin and adiponectin: a randomised study over 21 months,” Arthritis Research and Therapy, vol. 12, no. 5, article R197, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. A. Jamnitski, I. M. Visman, M. J. L. Peters, B. A. C. Dijkmans, A. E. Voskuyl, and M. T. Nurmohamed, “Beneficial effect of 1-year etanercept treatment on the lipid profile in responding patients with rheumatoid arthritis: the ETRA study,” Annals of the Rheumatic Diseases, vol. 69, no. 11, pp. 1929–1933, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. D. N. Kiortsis, A. K. Mavridis, T. D. Filippatos, S. Vasakos, S. N. Nikas, and A. A. Drosos, “Effects of infliximab treatment on lipoprotein profile in patients with rheumatoid arthritis and ankylosing spondylitis,” Journal of Rheumatology, vol. 33, no. 5, pp. 921–923, 2006. View at Google Scholar · View at Scopus
  21. K. Kume, K. Amano, S. Yamada, K. Hatta, H. Ohta, and N. Kuwaba, “Tocilizumab monotherapy reduces arterial stiffness as effectively as etanercept or adalimumab monotherapy in rheumatoid arthritis: an open-label randomized controlled trial,” The Journal of Rheumatology, vol. 38, no. 10, pp. 2169–2171, 2011. View at Google Scholar
  22. K. Nishida, Y. Okada, M. Nawata, K. Saito, and Y. Tanaka, “Induction of hyperadiponectinemia following long-term treatment of patients with rheumatoid arthritis with infliximab (IFX), an anti-TNF-alpha antibody,” Endocrine Journal, vol. 55, no. 1, pp. 213–216, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. M. J. L. Peters, M. Vis, V. P. van Halm et al., “Changes in lipid profile during infliximab and corticosteroid treatment in rheumatoid arthritis,” Annals of the Rheumatic Diseases, vol. 66, no. 7, pp. 958–961, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. C. Popa, M. G. Netea, T. Radstake et al., “Influence of anti-tumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis,” Annals of the Rheumatic Diseases, vol. 64, no. 2, pp. 303–305, 2005. View at Publisher · View at Google Scholar · View at Scopus
  25. C. Popa, F. H. J. van den Hoogen, T. R. D. J. Radstake et al., “Modulation of lipoprotein plasma concentrations during long-term anti-TNF therapy in patients with active rheumatoid arthritis,” Annals of the Rheumatic Diseases, vol. 66, no. 11, pp. 1503–1507, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. B. Seriolo, S. Paolino, A. Sulli, D. Fasciolo, and M. Cutolo, “Effects of anti-TNF-α treatment on lipid profile in patients with active rheumatoid arthritis,” Annals of the New York Academy of Sciences, vol. 1069, pp. 414–419, 2006. View at Publisher · View at Google Scholar · View at Scopus
  27. B. Seriolo, S. Paolino, C. Ferrone, and M. Cutolo, “Effects of etanercept or infliximab treatment on lipid profile and insulin resistance in patients with refractory rheumatoid arthritis,” Clinical Rheumatology, vol. 26, no. 10, pp. 1799–1800, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. M. Soubrier, P. Jouanel, S. Mathieu et al., “Effects of anti-tumor necrosis factor therapy on lipid profile in patients with rheumatoid arthritis,” Joint Bone Spine, vol. 75, no. 1, pp. 22–24, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. E. Spanakis, P. Sidiropoulos, J. Papadakis et al., “Modest but sustained increase of serum high density lipoprotein cholesterol levels in patients with inflammatory arthritides treated with infliximab,” Journal of Rheumatology, vol. 33, no. 12, pp. 2440–2446, 2006. View at Google Scholar · View at Scopus
  30. L. S. Tam, B. Tomlinson, T. T. Chu, T. K. Li, and E. K. Li, “Impact of TNF inhibition on insulin resistance and lipids levels in patients with rheumatoid arthritis,” Clinical Rheumatology, vol. 26, no. 9, pp. 1495–1498, 2007. View at Publisher · View at Google Scholar · View at Scopus
  31. M. Vis, M. T. Nurmohamed, G. Wolbink et al., “Short term effects of infliximab on the lipid profile in patients with rheumatoid arthritis,” Journal of Rheumatology, vol. 32, no. 2, pp. 252–255, 2005. View at Google Scholar · View at Scopus
  32. C. A. Wijbrandts, S. I. Van Leuven, H. D. Boom et al., “Sustained changes in lipid profile and macrophage migration inhibitory factor levels after anti-tumour necrosis factor therapy in rheumatoid arthritis,” Annals of the Rheumatic Diseases, vol. 68, no. 8, pp. 1316–1321, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. P. Emery, E. Keystone, H. P. Tony et al., “IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial,” Annals of the Rheumatic Diseases, vol. 67, no. 11, pp. 1516–1523, 2008. View at Publisher · View at Google Scholar · View at Scopus
  34. M. C. Genovese, J. D. McKay, E. L. Nasonov et al., “Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study,” Arthritis & Rheumatism, vol. 58, no. 10, pp. 2968–2980, 2008. View at Publisher · View at Google Scholar · View at Scopus
  35. G. Jones, A. Sebba, J. Gu et al., “Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study,” Annals of the Rheumatic Diseases, vol. 69, no. 1, pp. 88–96, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. S. Y. Kawashiri, A. Kawakami, S. Yamasaki et al., “Effects of the anti-interleukin-6 receptor antibody, tocilizumab, on serum lipid levels in patients with rheumatoid arthritis,” Rheumatology International, vol. 31, no. 4, pp. 451–456, 2011. View at Publisher · View at Google Scholar · View at Scopus
  37. R. N. Maini, P. C. Taylor, J. Szechinski et al., “Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate,” Arthritis & Rheumatism, vol. 54, no. 9, pp. 2817–2829, 2006. View at Publisher · View at Google Scholar · View at Scopus
  38. O. Schultz, F. Oberhauser, J. Saech et al., “Effects of inhibition of interleukin-6 signalling on insulin sensitivity and lipoprotein (A) levels in human subjects with rheumatoid diseases,” PLoS ONE, vol. 5, no. 12, Article ID e14328, 2010. View at Publisher · View at Google Scholar · View at Scopus
  39. J. S. Smolen, A. Beaulieu, A. Rubbert-Roth et al., “Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial,” The Lancet, vol. 371, no. 9617, pp. 987–997, 2008. View at Publisher · View at Google Scholar · View at Scopus
  40. C. Gonzalez-Juanatey, J. Llorca, T. R. Vazquez-Rodriguez, N. Diaz-Varela, H. Garcia-Quiroga, and M. A. Gonzalez-Gay, “Short-term improvement of endothelial function in rituximab-treated rheumatoid arthritis patients refractory to tumor necrosis factor α blocker therapy,” Arthritis Care and Research, vol. 59, no. 12, pp. 1821–1824, 2008. View at Publisher · View at Google Scholar · View at Scopus
  41. G. Kerekes, P. Soltész, H. Dér et al., “Effects of rituximab treatment on endothelial dysfunction, carotid atherosclerosis, and lipid profile in rheumatoid arthritis,” Clinical Rheumatology, vol. 28, no. 6, pp. 705–710, 2009. View at Publisher · View at Google Scholar · View at Scopus
  42. S. Mathieu, B. Pereira, J. J. Dubost, J. R. Lusson, and M. Soubrier, “No significant change in arterial stiffness in RA after 6 months and 1 year of rituximab treatment,” Rheumatology, vol. 51, no. 6, pp. 1107–1111, 2012. View at Google Scholar
  43. H. G. Raterman, H. Levels, A. E. Voskuyl, W. F. Lems, B. A. Dijkmans, and M. T. Nurmohamed, “HDL protein composition alters from proatherogenic into less atherogenic and proinflammatory in rheumatoid arthritis patients responding to rituximab,” Annals of the Rheumatic Diseases. In press.
  44. W. G. Dixon, K. D. Watson, M. Lunt et al., “Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor α therapy: Results from the British Society for Rheumatology Biologics Register,” Arthritis & Rheumatism, vol. 56, no. 9, pp. 2905–2912, 2007. View at Publisher · View at Google Scholar · View at Scopus
  45. C. Gonzalez-Juanatey, J. Llorca, A. Sanchez Andrade, C. Garcia-Porrua, J. Martin, and M. A. Gonzalez-Gay, “Short-term adalimumab therapy improves endothelial function in patients with rheumatoid arthritis refractory to infliximab,” Clinical and Experimental Rheumatology, vol. 24, no. 3, pp. 309–312, 2006. View at Google Scholar · View at Scopus
  46. A. Kontush and M. J. Chapman, “Antiatherogenic function of HDL particle subpopulations: focus on antioxidative activities,” Current Opinion in Lipidology, vol. 21, no. 4, pp. 312–318, 2010. View at Publisher · View at Google Scholar · View at Scopus
  47. A. V. Khera, M. Cuchel, M. De La Llera-Moya et al., “Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis,” The New England Journal of Medicine, vol. 364, no. 2, pp. 127–135, 2011. View at Google Scholar · View at Scopus
  48. J. Stock, “Importance of HDL functionality to cardiovascular risk,” Atherosclerosis, vol. 218, no. 1, pp. 19–20, 2011. View at Publisher · View at Google Scholar · View at Scopus
  49. B. J. Ansell, G. C. Fonarow, and A. M. Fogelman, “The paradox of dysfunctional high-density lipoprotein,” Current Opinion in Lipidology, vol. 18, no. 4, pp. 427–434, 2007. View at Publisher · View at Google Scholar · View at Scopus
  50. C. Charles-Schoeman, D. Khanna, D. E. Furst et al., “Effects of high-dose atorvastatin on antiinflammatory properties of high density lipoprotein in patients with rheumatoid arthritis: a pilot study,” Journal of Rheumatology, vol. 34, no. 7, pp. 1459–1464, 2007. View at Google Scholar · View at Scopus
  51. E. Arts, J. Fransen, H. Lemmers et al., “High-density lipoprotein cholesterol subfractions HDL2 and HDL3 are reduced in women with rheumatoid arthritis and may augment the cardiovascular risk of women with RA: a cross-sectional study,” Arthritis Research and Therapy, vol. 14, no. 3, article R116, 2012. View at Google Scholar
  52. D. P. M. Symmons and S. E. Gabriel, “Epidemiology of CVD in rheumatic disease, with a focus on RA and SLE,” Nature Reviews Rheumatology, vol. 7, no. 7, pp. 399–408, 2011. View at Publisher · View at Google Scholar · View at Scopus